Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31275318 | 0.80 | PRKCI (0.42) | PRKCIAHRPARP1MAPK1ZAP70 | |
| SCHEMBL2211568 | 0.80 | PRKCI (0.42) | PRKCIAHRPARP1MAPK1ZAP70 | |
| SCHEMBL2674588 | 0.77 | PIK3C3 (0.41) | PRKCIAHRPARP1MAPK1ZAP70 | |
| SCHEMBL31279052 | 0.77 | DYRK1A (0.44) | PRKCIAHRPARP1MAPK1ZAP70 | |
| SCHEMBL1763755 | 0.77 | DYRK1A (0.44) | PRKCIAHRPARP1MAPK1ZAP70 | |
| SCHEMBL21986162 | 0.77 | AXL (0.44) | PRKCIAXL | |
| SCHEMBL12033234 | 0.73 | PRKCI (0.41) | PRKCIAHRAXL | |
| SCHEMBL16336384 | 0.73 | PRKCI (0.37) | PRKCIAHR | |
| SCHEMBL16916862 | 0.73 | PRKCI (0.37) | PRKCIAHRAXL | |
| SCHEMBL31638924 | 0.73 | PRKCI (0.37) | PRKCIAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | PRKCI 4354/4885AHR 199/4885PARP1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.